We have been planning for this transition for many years. Today, neurology is a critical engine of success, and longer-term, regardless of the nature of the opportunity -- or which franchise it is currently allocated to -- our plan will always be to look toward our internal resources first for support.
I think this means neuro will fade off into the dust. In eighteen months, if you are still in neuro,you are F***ed
I can't think of a single company that thrives on only psych products. They just make no money as they can't differentiate in a highly generic market. Neuro sales, marketing, and Med affairs looks to be heading to chopping block ASAP.
Everest AMs picking up Northera for T1 in November. Only having Onfi for T3 this year. No change in territories till Onfi goes away in T3 of 2018. All Neuro AMs needed to naximuze Onfi sales
I do not believe that. With Rexulti failure for Alzheimer's today how do they justify keeping us... We were suppose to rotate to that drug when Onfi went off. Literally no future now...
This company has an awful clinical trial track record over the past few years. Can't even get an IV formulation of a 40 year old drug improved. Makes me sad.
Who in the hell does a study in the Russian Federation! They will never get this indication. Just another failure of upper management. I would love to ask them, "Now, what are you going to do differently?" This company is deep trouble. Wonder if they have a patient profile for this?
Desmotaplase-fail IV Carb-fail Trintellix cognition indication-fail Trintellix ADHD indication-fail Idalopirdine-fail Brex AD aggitation-fail
Well....well, that's uh, easy to explain, uh,uh. I know! I know! They didn't show a patient profile to the researchers before the trial began! And they didn't plan 500 conference calls/meetings with Otsuka and Takeda before, during, and after the trials! And, they obviously didn't do enough spreadsheets/trackers to see what they are going to do differently! There you have it! I knew I could explain all those failures! Seriously, Brex ALs Agitation is DOA (strange indication anyway), and they know it. What's worse is the HO and field knows it too. Watch the micromanagement, threats, CC's, alliance meetings, etc. ramp up big time.They are officially out of ammo.
Well I sure can see the above poster know shit about AZ disease. The agitation with AZ patients is REAL and is horrific to witness. The anti psychotic on the market now "usually" make them worse off . So ass wipe, learn about a disease state, prior to opening your pie hole.
Payers would require step edits through all generic anti-psychotics first. Not to mention ability, which is the exact same drug as me-too Brex.
Then Mr or Mrs Genius please elaborate to the group why a drug like Seroquel which is very sedating tried and failed to get the indication??? And how praytell is an atypical that is more activating going to work? Try again.
Yes, agitation is real, and is horrible, but this drug will never make it, period. You need 2 POSITIVE studies to submit for approval, and we only have 1! So, smart ass what will they have to do for an approval...drum roll.... DO AN ADDITIONAL STUDY OR MORE! It takes years to do a study! Thy will pull this drug because, (1) it's not that efficacious., and (2) it will take years to ever get an approval, which is doubtful. And there is NO atypical with that indication in the world, and brex won't be the first! And, you can forget about 35700. It's DOA!
It's so nice to see that Kare is buying back stock when they could use the cash reserves to acquire some medicines.... stock is up 300% in a few years... great job pleasing your investors and your bank account. So much for future vision and acquiring new molecules to sell
Well at least he's stuck to his word. He said we won't buy anything and everything we sell will be developed internally. Problem is that we currently suck at R@D, so we will only have crappy psych products to sell for next 10 years. I'm impressed we even have funds to keep the lights on!
